Zogenix, Inc. (ZGNX) Shares Bought by Alliancebernstein L.P.
Alliancebernstein L.P. boosted its stake in Zogenix, Inc. (NASDAQ:ZGNX) by 16.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,812 shares of the company’s stock after purchasing an additional 2,500 shares during the period. Alliancebernstein L.P. owned approximately 0.07% of Zogenix worth $258,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in shares of Zogenix during the 2nd quarter valued at $100,000. American International Group Inc. grew its position in shares of Zogenix by 7.1% during the 1st quarter. American International Group Inc. now owns 15,278 shares of the company’s stock valued at $166,000 after acquiring an additional 1,010 shares during the period. Metropolitan Life Insurance Co. NY grew its position in shares of Zogenix by 17.0% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 19,734 shares of the company’s stock valued at $214,000 after acquiring an additional 2,864 shares during the period. Trexquant Investment LP bought a new stake in shares of Zogenix during the 2nd quarter valued at $272,000. Finally, State of Wisconsin Investment Board bought a new stake in shares of Zogenix during the 2nd quarter valued at $275,000. 68.50% of the stock is owned by institutional investors and hedge funds.
In other news, major shareholder Life Sciences Maste Perceptive bought 300,000 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The shares were bought at an average price of $37.50 per share, for a total transaction of $11,250,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 5.00% of the stock is currently owned by insiders.
A number of equities research analysts have recently issued reports on ZGNX shares. Mizuho started coverage on shares of Zogenix in a research report on Wednesday, September 6th. They set a “buy” rating and a $28.00 price objective for the company. ValuEngine downgraded shares of Zogenix from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Stifel Nicolaus reissued a “buy” rating and set a $55.00 price objective (up previously from $26.00) on shares of Zogenix in a research report on Friday, September 29th. Zacks Investment Research raised shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub downgraded shares of Zogenix from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $40.00.
Zogenix, Inc. (NASDAQ:ZGNX) opened at $39.85 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.48 and a current ratio of 2.71. Zogenix, Inc. has a one year low of $7.70 and a one year high of $42.60.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/12/zogenix-inc-zgnx-shares-bought-by-alliancebernstein-l-p.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.